Belimumab
- Generic Name
- Belimumab
- Brand Names
- Benlysta
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 356547-88-1
- Unique Ingredient Identifier
- 73B0K5S26A
- Background
Belimumab is a fully human recombinant IgG1λ monoclonal antibody that inhibits soluble human B lymphocyte stimulator protein (BLyS, also referred to as BAFF and TNFSF13B), a B cell survival factor. BLyS levels are often elevated in immunodeficient and autoimmune disorders, such as systemic lupus erythematosus (SLE). By binding to BLyS and blocking its intera...
- Indication
In the US, belimumab is indicated to treat active systemic lupus erythematosus (SLE) and active lupus nephritis in patients aged five years and older who are receiving standard therapy. In Europe, belimumab is also used to treat SLE and lupus nephritis but only in adults.
...
- Associated Conditions
- Active Systemic Lupus Erythematosus, Lupus Nephritis
- Associated Therapies
- -
A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
- First Posted Date
- 2024-12-04
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 225
- Registration Number
- NCT06716606
- Locations
- 🇪🇸
GSK Investigational Site, VigoPontevedra, Spain
A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants and Healthy Chinese and Japanese Participants
- Conditions
- Interventions
- First Posted Date
- 2024-08-28
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 112
- Registration Number
- NCT06576271
- Locations
- 🇬🇧
GSK Investigational Site, Cambridge, United Kingdom
Belimumab After Rituximab in Resistant Primary Juvenile SS
- Conditions
- Interventions
- First Posted Date
- 2024-05-13
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 15
- Registration Number
- NCT06410833
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
Belimumab in SLE Synovial Inflammation and Lymph Nodes
- Conditions
- First Posted Date
- 2024-03-25
- Last Posted Date
- 2024-03-25
- Target Recruit Count
- 15
- Registration Number
- NCT06327724
- Locations
- 🇳🇱
Amsterdam UMC; location Academic Medical Center, Amsterdam, Netherlands
A Study of Belimumab in Chinese Pediatric Participants With Systemic Lupus Erythematosus
- Conditions
- Interventions
- First Posted Date
- 2023-06-23
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 13
- Registration Number
- NCT05917288
- Locations
- 🇨🇳
GSK Investigational Site, Suzhou, China
A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
- Conditions
- Interventions
- First Posted Date
- 2023-05-26
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 300
- Registration Number
- NCT05878717
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
The Efficacy and Safety of Telitacicept and Belimumab in Active Lupus Nephritis in the Real World: a Prospective Cohort Study
- Conditions
- Interventions
- First Posted Date
- 2022-10-20
- Last Posted Date
- 2022-10-20
- Target Recruit Count
- 60
- Registration Number
- NCT05588830
Belimumab In Prevention of LN
- Conditions
- First Posted Date
- 2022-10-19
- Last Posted Date
- 2022-10-19
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 48
- Registration Number
- NCT05585671
Efficacy and Immunological Evaluation of Belimumab Plus Low Dose IL-2 in the Treatment of Systemic Lupus Erythematosus
- First Posted Date
- 2022-03-02
- Last Posted Date
- 2022-03-25
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 10
- Registration Number
- NCT05262686
- Locations
- 🇨🇳
Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China
Efficacy and Safety of Belimumab in Neuromyelitis Optica Spectrum Disorders
- First Posted Date
- 2021-12-13
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Tianjin Medical University General Hospital
- Target Recruit Count
- 14
- Registration Number
- NCT05154734
- Locations
- 🇨🇳
Tianjin Medical University General Hospital, Tianjin, Tianjin, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.